ALTANA: Top line results of first one-year COPD study with Daxas
In the COPD study "RATIO/M2-112" the primary endpoint of lung function (FEV1) significantly improved with roflumilast treatment compared to placebo.The frequency of moderate and severe exacerbations was a co-primary endpoint. There was no statistically significant reduction in the rate of total exacerbations (7% reduction). The most common adverse events associated with roflumilast treatment were nausea, headache and diarrhea.
After the termination of the Daxas® collaboration with Pfizer ALTANA will continue the development of Daxas®. A marketing authorization application (MAA) for Daxas® is under evaluation by regulatory agencies in Europe.
Most read news
Topics
Organizations
Other news from the department research and development
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.